Recently, Kuzuya et al. reported the results of a small cohort study in which patients with u‐HCC with AFP >400 ng/mL were administered RAM treatment after LEN failure and showed promising therapeutic efficacy and safety, with DCR of 80%, median time to treatment progression of 3.1 months, and the incidence of grade 3 AEs of 10%.24 This evidence concerns the gene AFP and hepatocellular carcinoma.